Browsing by Author Matthews, David

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)Citation
2017Canagliflozin and cardiovascular and renal events in type 2 diabetesFulcher, Greg; Neal, Bruce; Perkovic, Vlado; de Zeeuw, Dick; Desai, Mehul; Erondu, N; Law, Gordon; Mahaffey, Kenneth W; Matthews, David; Shaw, Wayne; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthCanagliflozin and cardiovascular and renal events in type 2 diabetes, New England Journal of Medicine, vol.377, 7, 2017,pp 644-657
2015Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 DiabetesFulcher, Greg; Neal, Bruce; Perkovic, Vlado; Alba, Maria; Capuano, George; de Zeeuw, Dick; Desai, Mehul; Jiang, Joel; Mahaffey, Kenneth W; Matthews, David; Meininger, G; Shaw, Wayne; Vercruysse, Frank; Ways, Kirk; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthEfficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes, Diabetes Care, vol.38, 3, 2015,pp 403-411
2016Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ONChalmers, John; Li, Qiang; MacMahon, Stephen William; Neal, Bruce; Perkovic, Vlado; Rodgers, Anthony; Wong, Muh Geot; Woodward, Mark; Zoungas, Sophia; Cooper, Mark; Hamet, Pavel; Harrap, Stephen; Heller, Simon; Mancia, Giuseppe; Marre, Michel; Matthews, David; Poulter, Neil; Williams, Bryan; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthLong-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON, Diabetes Care, vol.39, 5, 2016,pp 694-700
2016Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON studyChalmers, John; Colagiuri, Stephen; Hirakawa, Yoichiro; Mohammedi, Kamel; Woodward, Mark; Zoungas, Sophia; Hamet, Pavel; Harrap, Stephen; Marre, Michel; Matthews, David; Poulter, Neil; The George Institute for Global Health; Boden Institute; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global HealthPresentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study, Cardiovascular Diabetology, vol.15, 1, 2016,pp 1-9
2017Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trialFulcher, Greg; Neal, Bruce; Perkovic, Vlado; de Zeeuw, Dick; Deng, Hsiaowei; Desai, Mehul; Erondu, N; Mahaffey, Kenneth W; Matthews, David; Meininger, Gary; Shaw, Wayne; Vercruysse, Frank; Yee, Jacqueline; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthRationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial, Diabetes, Obesity and Metabolism, vol.19, 3, 2017,pp 387-393
2013Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trialFulcher, Greg; Neal, Bruce; Perkovic, Vlado; de Zeeuw, Dick; Desai, Mehul; Jiang, Joel; Mahaffey, Kenneth; Matthews, David; Meininger, G; Shaw, Wayne; Stein, Peter; Vercruysse, Frank; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthRationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial, American Heart Journal, vol.166, 2, 2013,pp 217-223